PD-L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi's sarcoma

被引：10
|
作者：
Genovese, G. [1 ,2 ]
Venegoni, L. [2 ]
Fanoni, D. [2 ]
Tourlaki, A. [1 ]
Brambilla, L. [1 ]
Berti, E. [1 ,2 ]
机构：
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, UOC Dermatol, Milan, Italy
[2] Univ Milan, Dipartimento Fisiopatol Medicochirurg & Trapianti, Milan, Italy
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷 / 07期
关键词：
D O I：
10.1111/jdv.15543
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E269 / E271
页数：3
相关论文
共 50 条
  • [41] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [42] Pegylated Arginine Deiminase Potentiates PD-1/PD-L1 Immune Checkpoint Blockade in Malignant Mesothelioma
    Szlosarek, P.
    Khadeir, R.
    Sheaff, M.
    Locke, M.
    Lau, K.
    Wu, B.
    Bomalaski, J.
    Martin, S.
    Quezada, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1884 - S1884
  • [43] A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
    Koopmans, Iris
    Hendriks, Djoke
    Samplonius, Douwe F.
    van Ginkel, Robert J.
    Heskamp, Sandra
    Wierstra, Peter J.
    Bremer, Edwin
    Helfrich, Wijnand
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [44] A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
    Koopmans, Iris
    Samplonius, Douwe F.
    van Ginkel, Robert J.
    Wierstra, Peter J.
    Heskamp, Sandra
    Bremer, Edwin
    Helfrich, Wijnand
    CANCER RESEARCH, 2018, 78 (13)
  • [45] Molecular Biomarkers of Response to PD-1/PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
    Tu, Megan M.
    Ng, Terry L.
    De Jong, Horns C.
    Zuiverloon, Tahlita C. M.
    Fazzari, Francesco G. T.
    Theodorescu, Dan
    BLADDER CANCER, 2019, 5 (02) : 131 - 145
  • [46] The efficacy of PD-L1 blockade on PD-L1 negative medulloblastoma is dependent on timing and the tumor microenvironment
    Allen, Frederick
    Dorand, Rodney Dixon
    Rauhe, Peter
    Petrosiute, Agne
    Huang, Alex Y.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [47] PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
    Jin, Menglei
    Fang, Jun
    Peng, Junwen
    Wang, Xintian
    Xing, Ping
    Jia, Kunpeng
    Hu, Jianming
    Wang, Danting
    Ding, Yuxin
    Wang, Xinyu
    Li, Wenlu
    Chen, Zhigang
    MOLECULAR CANCER, 2024, 23 (01)
  • [48] PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
    Kim, Sang Kyum
    Kim, Jee Hung
    Kim, Seung Hyun
    Lee, Young Han
    Han, Jung Woo
    Baek, Wooyeol
    Woo, Ha Young
    Jeon, Min Kyung
    Kim, Hyo Song
    BMC CANCER, 2021, 21 (01)
  • [49] PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
    Sang Kyum Kim
    Jee Hung Kim
    Seung Hyun Kim
    Young Han Lee
    Jung Woo Han
    Wooyeol Baek
    Ha Young Woo
    Min Kyung Jeon
    Hyo Song Kim
    BMC Cancer, 21
  • [50] Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
    Meng, Xiangjiao
    Huang, Zhaoqin
    Teng, Feifei
    Xing, Ligang
    Yu, Jinming
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 868 - 876
12345